Objective:To investigate the efficacy of granulocyte colony-stimulating factor(G-CSF) in neoadjuvant chemotherapy(NAC) for breast cancer.Methods:A total of 56 stage Ⅱ,Ⅲ primary breast cancer patients who would receive NAC with bone marrow suppression risk assessment greater than 20% were randomly divided into preventive treatment(PT) group and conventional treatment(CT) group.The PT group patients(n=26) received bone marrow support treatment of G-CSF in 24 hours after the chemotherapy.The CT group patients(n=30) were reexamed blood routine test in 1,3,5 and 7 days after chemotherapy,and the patients who suffered grade Ⅲ and Ⅳ bone marrow suppression would receive G-CSF treatment.The differences of clinical complete remission(cCR), partial response(PR),stable disease(sD),disease progression(PD),bone marrow suppression and other side effects evaluation in the two groups were recorded and compared.Results:Two groups were comparable in age, menopausal status,pathological type and clinical stage(P>0.05).The bone marrow suppression and other adverse effects in PT group were significantly less than CT group(P<0.05).The clinical efficacy of conventional treatment was better than preventive treatment(P<0.05) in clinical cCR,PR,sD and PD.Conclusion:Compared with conventional bone marrow support therapy,preventive bone marrow support therapy significantly relieves the bone marrow toxicity and other adverse effects, increases patients' chemotherapy tolerance, and improves their life quality,but it is worse than CT group in the clinical efficacy of NAC.The specific mechanism needs further research. |
[1] 李席如,马冰,王建东,等.多西他赛联合表阿霉素新辅助治疗局部晚期乳腺癌的临床观察[J].中华外科杂志,2008,88(2):85-87.
[2] BENNETT C L,DJULBEGOVIC B,NORRIS L B,et al.Colo ny-stimulating factors for febrile neutropenia during cancer therapy[J].N Engl J Med,2013,368(12):1131-1139.
[3] ROBERT N,KREKOW L,STOKOE C,et al.Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-densenab-paclitaxel is safe in women with early-stage breast cancer:a pilot study[J].Breast Cancer Res Treat,2011,125(1):115-120.
[4] CRAWFORD J,DALE D C,LYMAN G H.Chemotherapy-induced neutrogena:risks,consequences,and new directions for its management[J].Cancer,2004,15(2):228.
[5] JOHNSTON E,CRAWFORD J,BLACKWELL S,et al.Randomized,dose-escalation study of SD/01 compared with daily filtrate in patients receiving chemotherapy [J].J Clin Oncol,2000,18(13):2522-2528.
[6] 汤鹏,李静,钟晓捷.氨磷汀联合粒生素预防乳腺癌化疗后所致白细胞减少的疗效观察[J].海南医学,2012,23(1):57-58.
[7] AAPRO M S,BOHLIUS J,CAMERON D A,et al.2010 Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile Neutrogena in adult patients with lymph proliferative disorders and solid tumors[J].Eur J Cancer,2011,47:8-32.
[8] SMITH T J,KHATCHERESSIAN J,LYMAN G H,et al.2006 update of recommendations for the use of white blood cell growth factors:an evidence-based clinical practice guideline[J].Clin Oncol,2006,24:3187-3205.
[9] RENNER P,MILAZZO S,LIU J P,et al.Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile Neutrogena in breast cancer patients[J].Cochrane Database Syst Rev,2012,17(10):CD007913.
[10] VOLOSHIN T,GINGIS-VELITSKI S,BRIL R,et al.G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth:prevention by a CXCR4 antagonist[J].Blood,2011,118(12):3426-3435.
[11] 程元甲,叶京明,徐玲,等.乳腺癌新辅助治疗病理完全缓解预测因素分析[J].中华外科杂志,2013,51(4):339-343. |